Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM — KMM-KCd  

Multiple Myeloma in Relapse Clinical Trial

Official title: A Phase II Study of Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Status Not yet recruiting

Clinical Trial Summary

This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.

Clinical Trial Description

The survival of multiple myeloma (MM) patients has been improved significantly owing to the adoption of immunomodulatory agents (IMiD) and proteasome inhibitors (PI). However, most of the MM patients finally experience relapse of refractoriness of the disease, of which patients who relapse after bortezomib and lenalidomide have very poor prognosis. Carfilzomib is an irreversible second generation PI which is approved by Korean FDA for RRMM in combination with dexamethasone and/or lenalidomide based on the landmark studies ASPIRE and ENDEAVOR studies. The addition of intravenous cyclophosphamide to carfilzomib has recently showed a promising result for RRMM patients after bortezomib and lenalidomide. In this study, cyclophosphamide 50mg orally will be added to carfilzomib once weekly schedule for 21 days daily every 4 weeks. The rationale for oral metronomic cyclophosphamide is based on previous experimental studies which has shown that it removes CD4+CD25+regulatory T cells preserving T and NK/T cell funtions. ;

Related Conditions & MeSH terms

• Multiple Myeloma
• Multiple Myeloma in Relapse
• Multiple Myeloma, Refractory
• Neoplasms, Plasma Cell

• NCT number: NCT05909826
• Study type: Interventional
• Source: Dong-A University Hospital
• Contact: Ji Hyun Lee, MD, Ph.D
• Phone: 82-51-240-2915
• Email: hidrleejh@dau.ac.kr
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 1, 2023
• Completion date: June 30, 2027